ATE545658T1 - Verfahren zur behandlung von synovialsarkom - Google Patents
Verfahren zur behandlung von synovialsarkomInfo
- Publication number
- ATE545658T1 ATE545658T1 AT04713982T AT04713982T ATE545658T1 AT E545658 T1 ATE545658 T1 AT E545658T1 AT 04713982 T AT04713982 T AT 04713982T AT 04713982 T AT04713982 T AT 04713982T AT E545658 T1 ATE545658 T1 AT E545658T1
- Authority
- AT
- Austria
- Prior art keywords
- synovial sarcoma
- treating
- treating synovial
- subject
- fzd10
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48619503P | 2003-07-11 | 2003-07-11 | |
PCT/JP2004/002144 WO2005004912A1 (en) | 2003-07-11 | 2004-02-24 | Method for treating synovial sarcoma |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE545658T1 true ATE545658T1 (de) | 2012-03-15 |
Family
ID=34062116
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04713982T ATE545658T1 (de) | 2003-07-11 | 2004-02-24 | Verfahren zur behandlung von synovialsarkom |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1648506B1 (de) |
JP (1) | JP4691626B2 (de) |
AT (1) | ATE545658T1 (de) |
ES (1) | ES2381841T3 (de) |
WO (1) | WO2005004912A1 (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7803370B2 (en) | 2002-08-30 | 2010-09-28 | Oncotherapy Science, Inc. | Method for treating synovial sarcoma |
EP1561759B9 (de) | 2002-10-11 | 2009-08-26 | Chugai Seiyaku Kabushiki Kaisha | Zelltod-induzierender wirkstoff |
US9241994B2 (en) | 2005-06-10 | 2016-01-26 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions containing sc(Fv)2 |
KR101367544B1 (ko) | 2005-06-10 | 2014-02-26 | 추가이 세이야쿠 가부시키가이샤 | 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용 |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
EP1961065A4 (de) * | 2005-10-31 | 2009-11-11 | Oncomed Pharm Inc | Zusammensetzungen und verfahren zur diagnostizierung und behandlung von krebs |
JP5028635B2 (ja) * | 2006-06-21 | 2012-09-19 | オンコセラピー・サイエンス株式会社 | Fzd10に対する腫瘍標的化モノクローナル抗体とその使用 |
EP2084540A2 (de) * | 2006-11-14 | 2009-08-05 | Novartis Ag | Verfahren für behandlung, diagnostizierung bzw. nachweis von krebs |
CL2008000719A1 (es) * | 2007-03-12 | 2008-09-05 | Univ Tokushima Chugai Seiyaku | Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a |
AU2009296246B2 (en) | 2008-09-26 | 2015-07-30 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
NZ602700A (en) | 2010-04-01 | 2014-10-31 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
CA2839755A1 (en) | 2011-06-17 | 2012-12-20 | President And Fellows Of Harvard College | Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer |
AU2012295394B2 (en) * | 2011-08-12 | 2016-04-14 | Omeros Corporation | Anti-FZD10 monoclonal antibodies and methods for their use |
WO2013157410A1 (ja) * | 2012-04-17 | 2013-10-24 | Hoya株式会社 | Fzd10結合性ペプチド |
AU2013334790A1 (en) | 2012-10-23 | 2015-04-30 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using Wnt pathway-binding agents |
EP2950885B1 (de) | 2013-02-04 | 2018-11-21 | Oncomed Pharmaceuticals, Inc. | Verfahren und überwachung einer behandlung mit einem wnt-pfad-hemmer |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
TWI762516B (zh) | 2016-10-06 | 2022-05-01 | 日商腫瘤療法 科學股份有限公司 | 針對fzd10之單株抗體及其用途 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
GB9414580D0 (en) * | 1994-07-19 | 1994-09-07 | Cancer Res Campaign Tech | Materials and methods relating to the diagnosis of synovial sarcomas |
US5994098A (en) * | 1997-06-02 | 1999-11-30 | Smithkline Beecham Corporation | Human 7-TM receptor similar to murine frizzled-6 gene |
EP0943684A3 (de) * | 1998-03-10 | 2002-01-23 | Smithkline Beecham Plc | Frizzled-ähnliche Polypeptide und Polynukleotide |
GB9819681D0 (en) * | 1998-09-09 | 1998-11-04 | Smithkline Beecham Plc | Novel compounds |
WO2002055705A2 (en) * | 2001-01-11 | 2002-07-18 | Curagen Corp | Proteins and nucleic acids encoding same |
US20030044409A1 (en) * | 2001-05-01 | 2003-03-06 | Carson Dennis A. | Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens |
-
2004
- 2004-02-24 AT AT04713982T patent/ATE545658T1/de active
- 2004-02-24 WO PCT/JP2004/002144 patent/WO2005004912A1/en active Application Filing
- 2004-02-24 EP EP04713982A patent/EP1648506B1/de not_active Expired - Lifetime
- 2004-02-24 JP JP2006518502A patent/JP4691626B2/ja not_active Expired - Lifetime
- 2004-02-24 ES ES04713982T patent/ES2381841T3/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1648506A1 (de) | 2006-04-26 |
JP4691626B2 (ja) | 2011-06-01 |
WO2005004912A1 (en) | 2005-01-20 |
ES2381841T3 (es) | 2012-06-01 |
EP1648506B1 (de) | 2012-02-15 |
JP2007526891A (ja) | 2007-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE545658T1 (de) | Verfahren zur behandlung von synovialsarkom | |
ATE390142T1 (de) | Synergistische zusammensetzung zur behandlung von diabetes mellitus | |
BR9407047A (pt) | Processo para separaçao de uma proteina de uma soluçao aquosa de proteinas | |
ATE476990T1 (de) | Cd20-bindende polypeptidzusammensetzungen | |
KR101155294B1 (ko) | 면역특이적으로 BLyS에 결합하는 항체 | |
EA200501891A1 (ru) | Гуманизированные антитела, распознающие бета-амилоидный пептид | |
ATE330631T1 (de) | Antikörperfragmente zur lokalen behandlung von augenerkrankungen | |
DE60215787D1 (de) | Behandlung von typ ii diabetes mit dipeptidyl-peptidase-iv-hemmern | |
ATE435012T1 (de) | Verfahren zur behandlung von parkinson-krankheit | |
DE60039783D1 (de) | Lfa-1 antagonisten und tnf-alpha antagonisten zur | |
DE60027732D1 (de) | Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems | |
BR9502707A (pt) | Composto composição farmacêutica e método para o tratamento de uma afecção | |
ATE250932T1 (de) | Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer | |
ATE521357T1 (de) | Verfahren zur behandlung von hepatitis | |
ATE496892T1 (de) | Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen | |
DE602004031134D1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
EA200401341A1 (ru) | Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания | |
ATE320803T1 (de) | Verfahren zur behandlung von alzheimerschen krankheit | |
ATE315390T1 (de) | Zyklische polyamine zur behandlung der thrombozytopenie | |
ATE292801T1 (de) | Verfahren zum screening von inhibitoren von asp2 | |
WO2004020668A3 (en) | Method for treating synovial sarcoma | |
CR6528A (es) | Metodo para inhibir la agregcion de proteinas amiloidesy formacion de imagenes de depositos amiloides | |
ATE484294T1 (de) | Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen | |
DE602005013650D1 (de) | Proteinhydrolysat zur behandlung von müdigkeit | |
DE69619187T2 (de) | Verfahren zur behandlung von motorischen defiziten |